CL2024001073A1 - Inhibidores de la replicación del virus de inmunodeficiencia humana - Google Patents

Inhibidores de la replicación del virus de inmunodeficiencia humana

Info

Publication number
CL2024001073A1
CL2024001073A1 CL2024001073A CL2024001073A CL2024001073A1 CL 2024001073 A1 CL2024001073 A1 CL 2024001073A1 CL 2024001073 A CL2024001073 A CL 2024001073A CL 2024001073 A CL2024001073 A CL 2024001073A CL 2024001073 A1 CL2024001073 A1 CL 2024001073A1
Authority
CL
Chile
Prior art keywords
inhibitors
immunodeficiency virus
human immunodeficiency
virus replication
formula
Prior art date
Application number
CL2024001073A
Other languages
English (en)
Spanish (es)
Inventor
Dalwadi Gautam
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of CL2024001073A1 publication Critical patent/CL2024001073A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024001073A 2021-10-13 2024-04-11 Inhibidores de la replicación del virus de inmunodeficiencia humana CL2024001073A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163255056P 2021-10-13 2021-10-13
US202163257212P 2021-10-19 2021-10-19

Publications (1)

Publication Number Publication Date
CL2024001073A1 true CL2024001073A1 (es) 2024-10-04

Family

ID=84044276

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001073A CL2024001073A1 (es) 2021-10-13 2024-04-11 Inhibidores de la replicación del virus de inmunodeficiencia humana

Country Status (10)

Country Link
US (1) US20240423985A1 (enExample)
EP (1) EP4415685A1 (enExample)
JP (1) JP2024535596A (enExample)
KR (1) KR20240074850A (enExample)
AU (1) AU2022362855B2 (enExample)
CA (1) CA3234219A1 (enExample)
CL (1) CL2024001073A1 (enExample)
IL (1) IL311982A (enExample)
MX (1) MX2024004551A (enExample)
WO (1) WO2023062559A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
TW202547514A (zh) 2024-02-05 2025-12-16 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119462611A (zh) * 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
TWI687415B (zh) * 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
KR20210033492A (ko) * 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
BR112021025655A2 (pt) * 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
BR112022020933A2 (pt) * 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana

Also Published As

Publication number Publication date
CA3234219A1 (en) 2023-04-20
IL311982A (en) 2024-06-01
JP2024535596A (ja) 2024-09-30
AU2022362855B2 (en) 2025-08-14
US20240423985A1 (en) 2024-12-26
MX2024004551A (es) 2024-06-26
AU2022362855A1 (en) 2024-05-02
KR20240074850A (ko) 2024-05-28
WO2023062559A1 (en) 2023-04-20
EP4415685A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
SA522432955B1 (ar) Kras g12c مثبطات
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
GEAP202416435A (en) Anti-viral compounds
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
PY2121402A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
CL2024000593A1 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
SA521422143B1 (ar) 15-pgdh مثبط
EA202193007A1 (ru) Соединения пирролидина
PH12021553180A1 (en) Inhibitors of human immunodeficiency virus replication
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
SA521421645B1 (ar) بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
EA201391018A1 (ru) Препараты иммуносупрессантов
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
MX2022011016A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
EA202092159A1 (ru) Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение